Micro-dystrophin expression as a surrogate endpoint for Duchenne muscular dystrophy clinical trials.
Human gene therapy(2023)
Abstract
Duchenne muscular dystrophy (DMD) is a serious, rare genetic disease, affecting primarily boys. It is caused by mutations in the DMD gene and is characterized by progressive muscle degeneration that results in loss of function and early death due to respiratory and/or cardiac failure. Although limited treatment options are available, some for only small subsets of the patient population, DMD remains a disease with large unmet medical needs. The adeno-associated virus (AAV) vector is the leading gene delivery system for addressing genetic neuromuscular diseases. Since the gene encoding the full-length dystrophin protein exceeds the packaging capacity of a single AAV vector, gene replacement therapy based on AAV-delivery of shortened yet functional micro-dystrophin genes has emerged as a promising treatment. This paper seeks to explain the rationale for use of the accelerated approval pathway to advance AAV micro-dystrophin gene therapy for DMD. Specifically, we provide support for the use of micro-dystrophin expression as a surrogate endpoint that could be used in clinical trials to support accelerated approval.
MoreTranslated text
Key words
microdystrophin,Duchenne muscular dystrophy,gene therapy,AAV vector
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined